Amarin (AMRN) Could See Action on Takeover Report
Tweet Send to a FriendGet Alerts AMRN Hot Sheet
Up)
Trade AMRN Now!
Amarin Corporation plc (NASDAQ: AMRN) could see action Wednesday following reports from the UK's Daily Mail that AstraZeneca (NYSE: AZN) plans to launch a bid for the company.
While certainly to create a stir, the article appear very speculative in nature. That, and the fact that takeover speculation has been surrounding the name for months could keep a lid on things. Also, shares of Amarin rose 4.7 percent Tuesday on - you guessed it - takeover speculation.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
While certainly to create a stir, the article appear very speculative in nature. That, and the fact that takeover speculation has been surrounding the name for months could keep a lid on things. Also, shares of Amarin rose 4.7 percent Tuesday on - you guessed it - takeover speculation.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: ViroPharma (VPHM) on the Move Following Takeover Chatter - Reuters
- BlackBerry (BBRY) Deal 'Safe' Following Nokia (NOK) Chatter
- UPDATE: Nokia Corp (NOK) Pops as Huawei May Consider Buying the Company
Create E-mail Alert Related Categories
Rumors, Trader TalkComments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
not really
cloo on Oct 24, 2012 08:54 AMMark as Spam | Reply to this comment
Tuesday's rally was on the issuance of U.S. Patents 8,793,727 and 8,293,728 for Vascepa. One more patent next Friday. Don't think AZN can properly price buyout until NCE resolved which may be waiting for these patents.